Osteoarthritis of hip
Methodology & AI Transparency ⓘ
Osteoarthritis of hip Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry M16.9: Osteoarthritis of hip is managed within Arthritis & Joints.
- 3 Typical cash cost range: Clinicians assessing Osteoarthritis of hip focus on monosodium urate or in Osteoarthritis of hip (M16.9: calcium pyrophosphate crystal) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Osteoarthritis of hip: maintaining Serum Uric Acid in Osteoarthritis of hip (M16.9: (Gout Target)) within < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M16.9).
Ask our AI Specialists anything about Osteoarthritis of hip
What Is Osteoarthritis of hip?
Recognized across U.S. clinical coding as M16.9 (Arthritis & Joints), Osteoarthritis of hip is evaluated via serum urate/inflammatory marker in Osteoarthritis of hip (M16.9: profiling) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Osteoarthritis of hip (M16.9) features monosodium urate or in Osteoarthritis of hip (M16.9: calcium pyrophosphate crystal). therapeutic stabilization in arthritis & joints is verified against hs-CRP & Erythrocyte in Osteoarthritis of hip (M16.9: Sedimentation Rate).
Common Symptoms & Clinical Signs
- • Presentation of Osteoarthritis of hip (M16.9): brief morning joint in Osteoarthritis of hip (M16.9: stiffness)
- • Secondary Osteoarthritis of hip clinical sign: sudden, intensely painful, in Osteoarthritis of hip (M16.9: red swollen big-toe)
- • Symptom flares in Osteoarthritis of hip correlating with Serum Uric Acid in Osteoarthritis of hip (M16.9: (Gout Target)) deviation outside < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M16.9)
- • Functional arthritis & joints impact requiring serum urate/inflammatory marker in Osteoarthritis of hip (M16.9: profiling) evaluation (M16.9)
Osteoarthritis of hip Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M16.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Uric Acid in Osteoarthritis of hip (M16.9: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M16.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Osteoarthritis of hip (M16.9: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M16.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Osteoarthritis of hip M16.9] | Preserved joint-space width (M16.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Osteoarthritis of hip
Treatment selection for Osteoarthritis of hip depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Osteoarthritis of hip)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Exercise Type and Duration on Pain, Function, and Quality of Life in Patients: What a 3,808-Participant Study Found J Orthop Sports Phys Ther 2026;56(11):724-734. The Journal of orthopaedic and sports physical therapy • 2026-11-15 • Meta-Analysis | N = 3,808 | 94/100 | PMID 42966901 ↗ |
| New Insights on A single intra-articular injection of JTA-004, a combination of human plasma,: What a 746-Participant Study Found A single IA injection of JTA-004 was not superior to a saline solution (LSmean difference: -1.50 mm, 95%CI 5.12; 2.12, p= 0.42) or Synvisc-One® (LSmean difference: 2.40, 95% CI: -1.22; 6.02, p=0.20) for the treatment of OA... Osteoarthritis and cartilage • 2026-02-15 • Phase III Randomized Trial | N = 746 | 93/100 | PMID 41015076 ↗ |
| New Insights on A Phase 3, 28-week, multicentre, randomised, gold-standard blind, compared: What a 498-Participant Study Found LOR was well tolerated despite not meeting the primary endpoint. Clinical and experimental rheumatology • 2025-05-15 • Phase III Randomized Trial | N = 498 | 93/100 | PMID 39808288 ↗ |
| New Insights on A Phase 3, 56-week, randomised, gold-standard blind, compared against a dummy: What a 513-Participant Study Found 513 patients were randomised. Clinical and experimental rheumatology • 2025-05-15 • Phase III Randomized Trial | N = 513 | 93/100 | PMID 39808286 ↗ |
| New Insights on Efficacy of duloxetine for multisite pain in patients with knee pain due to: What a 353-Participant Study Found These results are consistent with duloxetine enhancing the activity of descending inhibitory pain pathways that are dysfunctional in patients with central sensitization and multisite pain. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association • 2021-01-15 • Phase III Randomized Trial | N = 353 | 93/100 | PMID 32245696 ↗ |
Osteoarthritis of hip Patient Community & “People Like Me” Threads
Filter Osteoarthritis of hip community threads and patient logs by age, biological sex, dosage, and treatment duration.